Eiko Lifesciences Limited has announced the completion of a significant preferential issue, allotting 6,25,000 equity shares and 29,50,000 warrants to promoters and investors. The Board of Directors approved this allotment on February 24, 2026, under the regulatory framework of SEBI regulations and the Companies Act, 2013.

Equity Share Allotment Details

The company allotted 6,25,000 equity shares with a face value of Rs. 10 each at a price of Rs. 55 per share, including a premium of Rs. 45 per share. The total amount raised through equity shares aggregated to Rs. 3,43,75,000.

Warrant Allotment Structure

The warrant allotment comprised 29,50,000 warrants, each convertible into one equity share at Rs. 55 per share. The company received Rs. 4,05,62,500, representing 25% of the total conversion amount of Rs. 16,22,50,000.

Regulatory Compliance and Share Rights

The preferential issue was conducted under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company has secured in-principle approval from BSE Limited for the issue of both equity shares and warrants on a preferential basis.

All newly allotted shares will rank pari-passu with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders. The allotment was approved through board circulation and communicated to the stock exchange under Regulation 30 of SEBI LODR Regulations, 2015.

Eiko lifesciences Limited successfully concluded its first Extra-Ordinary General Meeting (EOGM) on January 7, 2026, with shareholders approving two significant special resolutions related to preferential share issuance. The meeting was conducted at 3:00 PM IST through video conferencing in compliance with the Companies Act, 2013 and relevant regulatory circulars.

Meeting Overview and Participation

The EOGM witnessed active participation from shareholders across categories. A total of 21 shareholders attended the meeting through video conferencing, comprising 5 promoters and promoter group members and 16 public shareholders. The company had 3,186 total shareholders on the record date of January 2, 2026.

Voting Process and Timeline

The voting process was conducted through both remote e-voting and e-voting during the meeting. Remote e-voting commenced on January 4, 2026, at 9:00 AM IST and concluded on January 6, 2026, at 5:00 PM IST. Additionally, e-voting facility was provided during the EOGM and extended up to 15 minutes after the meeting's conclusion. The scrutinizer's report was prepared by Shravan A. Gupta, Practicing Company Secretary, who was appointed by the Board of Directors on December 11, 2025.

Resolution 1: Warrant Issuance Approval

The first special resolution for the issuance of 33,00,000 warrants convertible into equity shares on preferential basis received overwhelming support from shareholders.

The resolution was approved with 28 voters supporting and only 1 voter opposing. Notably, 5,148,842 votes from promoters and pre-preferential holders were considered invalid as they were interested parties in the resolution.

Resolution 2: Equity Share Issuance Approval

The second special resolution for the issuance of 6,75,000 equity shares on preferential basis also received strong shareholder approval.

This resolution was supported by 27 voters with 2 voters opposing. Similar to the first resolution, votes from promoters and pre-preferential holders totaling 5,148,842 were treated as invalid due to their interest in the resolution.

Regulatory Compliance and Documentation

The company ensured full compliance with regulatory requirements under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The voting results and scrutinizer's report were submitted to BSE Limited on January 9, 2026, with scrip code 540204. The electronic notice and explanatory statements were distributed to shareholders on December 11, 2025, with appropriate provisions for shareholders without registered email addresses.

Conclusion

Both special resolutions were passed with the requisite majority, enabling Eiko LifeSciences Limited to proceed with its capital raising plans through preferential issuance. The high approval rates of 99.9999% for both resolutions demonstrate strong shareholder confidence in the company's strategic initiatives. The successful conduct of the EOGM through digital means reflects the company's adherence to modern governance practices while maintaining transparency and regulatory compliance.